| #1 | Gamma entrainment therapy to restore hippocampal-cortical synchrony | SST | 0.946 | $0.60 | SDA-2026-04-03-26abc |
| #2 | Microglial-Mediated Tau Clearance Dysfunction via TREM2 Receptor Impairment | MAPT | 0.937 | $0.55 | SDA-2026-04-03-26abc |
| #3 | APOE-Dependent Autophagy Restoration | MTOR | 0.895 | $0.66 | SDA-BIOMNI-SURVIVAL- |
| #4 | SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence | SIRT1 | 0.893 | $0.60 | SDA-2026-04-03-gap-a |
| #5 | TREM2-APOE Axis Dissociation for Selective DAM Activation | TREM2-APOE axis | 0.886 | $0.64 | SDA-2026-04-01-gap-0 |
| #6 | Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 palmitoylation stabilization | BDNF | 0.885 | $0.61 | SDA-2026-04-03-26abc |
| #7 | Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated Autophagy Through PV Interneuron-Specific ceRNA Networks | PVALB, CREB1, lncRNA-9969, neuronal autophagy pathway | 0.865 | $0.60 | SDA-2026-04-26-gap-p |
| #8 | TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Transition | NAMPT | 0.862 | $0.66 | SDA-BIOMNI-VARIANT_- |
| #9 | Senescent Cell ASM-Complement Cascade Intervention | SMPD1 | 0.852 | $0.69 | SDA-2026-04-01-gap-l |
| #10 | Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration | SMPD3 | 0.844 | $0.69 | SDA-2026-04-01-gap-l |
| #11 | TREM2 Deficiency Drives Microglial Senescence via Lipid Metabolism Dysregulation | TREM2/TYROBP | 0.836 | $0.65 | SDA-2026-04-06-gap-p |
| #12 | AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses | PRKAA1 | 0.833 | $0.72 | sda-2026-04-01-gap-v |
| #13 | Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling | TREM2 | 0.827 | $0.60 | SDA-2026-04-03-26abc |
| #14 | Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-Autonomous Neurodegeneration | NLRP3, CASP1, IL1B, PYCARD | 0.822 | $0.60 | SDA-2026-04-01-gap-2 |
| #15 | Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation | BDNF | 0.820 | $0.65 | SDA-2026-04-03-26abc |
| #16 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.814 | $0.60 | SDA-2026-04-04-gap-t |
| #17 | SLC7A11 System Activation Restores Cystine Uptake and GSH Synthesis to Prevent Neuronal and Endothelial Ferroptosis After Cardiac Arrest | SLC7A11 (system Xc-) and GPX4 | 0.812 | $0.63 | SDA-2026-04-26-gap-p |
| #18 | LRP1-Dependent Tau Uptake Disruption | LRP1 | 0.808 | $0.62 | SDA-2026-04-04-gap-t |
| #19 | Neutrophil Extracellular Trap (NET) Inhibition | PADI4 | 0.806 | $0.68 | SDA-2026-04-16-gap-b |
| #20 | p16^INK4a-CCF Axis as Senolytic Timing Biomarker | CDKN2A, CGAS, STING1 | 0.805 | $0.57 | SDA-2026-04-07-gap-d |
| #21 | TREM2-mTOR Co-Agonism for Metabolic Reprogramming | TREM2-mTOR pathway | 0.803 | $0.60 | SDA-2026-04-01-gap-0 |
| #22 | Dual-Receptor Antibody Shuttling | - | 0.803 | $0.60 | - |
| #23 | Microglial TREM2-SYK Pathway Enhancement | TREM2 | 0.798 | $0.58 | SDA-2026-04-03-gap-s |
| #24 | Closed-loop transcranial focused ultrasound targeting CA1 PV interneurons with real-time gamma feedback to prevent tau propagation and restore hippocampal-prefrontal synchrony in Alzheimer's disease | PVALB | 0.797 | $0.55 | SDA-2026-04-03-26abc |
| #25 | Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) | APOE | 0.795 | $0.59 | sda-2026-04-01-gap-0 |
| #26 | VCP-Mediated Autophagy Enhancement | VCP | 0.787 | $0.59 | SDA-2026-04-04-gap-t |
| #27 | Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activate AMPK-autophagy flux and degrade intracellular tau before exosomal packaging in Alzheimer's disease | SST | 0.784 | $0.57 | SDA-2026-04-03-26abc |
| #28 | Selective Acid Sphingomyelinase Modulation Therapy | SMPD1 | 0.782 | $0.65 | SDA-2026-04-01-gap-l |
| #29 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.780 | $0.59 | SDA-2026-04-04-gap-t |
| #30 | TFEB Nuclear Translocation to Reset Lysosomal-Hypoxia Axis | TFEB, MTOR | 0.779 | $0.59 | SDA-2026-04-13-gap-p |
| #31 | Transcriptional Autophagy-Lysosome Coupling | FOXO1 | 0.777 | $0.63 | sda-2026-04-01-gap-0 |
| #32 | TREM2-APOE4 Co-targeting — Simultaneous Correction of Lipid Sensing and Clearance Deficits | TREM2, APOE | 0.774 | $0.61 | SDA-2026-04-02-gap-0 |
| #33 | Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation | FCGRT | 0.773 | $0.58 | sda-2026-04-01-gap-0 |
| #34 | TBK1-OPTN-NDP52 Phospho-Cascade Coordinates Multi-Organelle Autophagy | TBK1, OPTN (TBC1D7), NDP52/CALCOCO2 | 0.772 | $0.60 | SDA-2026-04-07-gap-p |
| #35 | Hypothesis 2: GPNMB-CD44 Axis as Anti-inflammatory Pathway | GPNMB, CD44 | 0.772 | $0.60 | SDA-2026-04-26-gap-p |
| #36 | p21^Cip1 Phospho-State as Autophagy Responsiveness Predictor | CDKN1A, CDK4, CDK6, ATM, PPP1CA | 0.768 | $0.61 | SDA-2026-04-07-gap-d |
| #37 | Chromatin Accessibility Restoration via BRD4 Modulation | BRD4 | 0.768 | $0.60 | SDA-2026-04-04-gap-e |
| #38 | CYP46A1 Overexpression Gene Therapy | CYP46A1 | 0.768 | $0.65 | SDA-2026-04-01-gap-l |
| #39 | Lysosomal Cathepsin-Dependent Tau Clearance | - | 0.767 | $0.62 | SDA-2026-04-26-gap-p |
| #40 | APOE4 Allosteric Rescue via Small Molecule Chaperones | APOE | 0.765 | $0.60 | sda-2026-04-01-gap-0 |
| #41 | Circadian Clock-Autophagy Synchronization | CLOCK | 0.763 | $0.58 | sda-2026-04-01-gap-v |
| #42 | Cell-Type Specific TREM2 Upregulation in DAM Microglia | TREM2 | 0.761 | $0.57 | analysis-SEAAD-20260 |
| #43 | Targeted APOE4-to-APOE3 Base Editing Therapy | APOE | 0.758 | $0.63 | sda-2026-04-01-gap-0 |
| #44 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.755 | $0.59 | test-hypothesis-fixt |
| #45 | GFAP-Positive Reactive Astrocyte Subtype Delineation | GFAP | 0.754 | $0.59 | analysis-SEAAD-20260 |
| #46 | Temporal SPP1 Inhibition During Critical Windows | SPP1 | 0.752 | $0.67 | SDA-2026-04-15-gap-p |
| #47 | Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection | MAPT | 0.751 | $0.57 | SDA-2026-04-03-26abc |
| #48 | Circadian-Synchronized Proteostasis Enhancement | CLOCK/ULK1 | 0.744 | $0.57 | sda-2026-04-01-gap-0 |
| #49 | Senescent Cell Mitochondrial DNA Release | CGAS/STING1/DNASE2 | 0.742 | $0.58 | sda-2026-04-01-gap-0 |
| #50 | PARP1 Inhibition Therapy | PARP1 | 0.738 | $0.63 | sda-2026-04-01-gap-0 |
| #51 | SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction | SIRT3 | 0.738 | $0.57 | SDA-2026-04-03-gap-s |
| #52 | H2: Impaired Autophagy Receptor Recruitment Traps G3BP1 Granules | TBK1, SQSTM1/p62, OPTN, NDP52 | 0.737 | $0.58 | SDA-2026-04-06-gap-p |
| #53 | Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Antagonist in Tau Phase | TREM2, APOE, MAPT | 0.735 | $0.58 | SDA-2026-04-02-gap-0 |
| #54 | SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysosomal Degradation via Autophagosome-Lysosome Fusion Dysfunction | SGMS1, BECN1 | 0.734 | $0.60 | SDA-2026-04-15-gap-p |
| #55 | SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regulation | SMPD1 | 0.732 | $0.61 | SDA-2026-04-15-gap-d |
| #56 | Senescence-Associated Myelin Lipid Remodeling | PLA2G6/PLA2G4A | 0.732 | $0.55 | sda-2026-04-01-gap-0 |
| #57 | Selective Neutral Sphingomyelinase-2 Inhibition Therapy | SMPD3 | 0.731 | $0.59 | SDA-2026-04-01-gap-l |
| #58 | Phase-Separated Organelle Targeting | G3BP1 | 0.729 | $0.60 | sda-2026-04-01-gap-0 |
| #59 | TFEB/TFE3 Parallel Activation Drives Coordinated Organelle Clearance via CLEAR Network | TFEB (TFEB), TFE3 (TFE3), mTORC1 (MTOR) | 0.727 | $0.60 | SDA-2026-04-07-gap-p |
| #60 | Synthetic Biology BBB Endothelial Cell Reprogramming | TFR1, LRP1, CAV1, ABCB1 | 0.727 | $0.57 | sda-2026-04-01-gap-0 |
| #61 | Metabolic Switch Targeting for A1→A2 Repolarization | HK2 | 0.726 | $0.57 | sda-2026-04-01-gap-0 |
| #62 | Microglial TREM2-Complement Axis Modulation | TREM2 and C3 | 0.726 | $0.60 | SDA-2026-04-03-gap-s |
| #63 | Astrocyte-Mediated Neuronal Epigenetic Rescue | HDAC | 0.725 | $0.57 | SDA-2026-04-04-gap-e |
| #64 | TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimination Through Type I IFN Hyperactivation | TBK1 | 0.724 | $0.60 | SDA-2026-04-13-gap-p |
| #65 | Autophagic Receptor Sequestration via K63-Ub 'Signalone' Recognition | G3BP1 | 0.720 | $0.60 | SDA-2026-04-07-gap-p |
| #66 | VCP/p97 ATPase mutations impair extraction of ubiquitinated autophagy substrates, causing proteasome-autophagy flux obstruction | VCP | 0.720 | $0.60 | SDA-2026-04-08-gap-p |
| #67 | Stress Granule Phase Separation Modulators | G3BP1 | 0.720 | $0.66 | sda-2026-04-01-gap-v |
| #68 | TREM2-DAP12 Signalosome Enhancement — Boosting PI3K-AKT-mTOR Axis for Microglial Metabolic Fitness | TREM2, TYROBP, SYK, PI3K | 0.718 | $0.58 | SDA-2026-04-02-gap-0 |
| #69 | APOE Isoform Conversion Therapy | APOE | 0.718 | $0.59 | sda-2026-04-01-gap-a |
| #70 | C9orf72 DPRs Impair Autophagy Receptor Docking on Stress Granules | C9orf72, p62/SQSTM1, OPTN | 0.717 | $0.60 | SDA-2026-04-06-gap-p |
| #71 | TREM2-ASM Crosstalk in Microglial Lysosomal Senescence | SMPD1 | 0.713 | $0.61 | SDA-2026-04-03-gap-a |
| #72 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.712 | $0.59 | test-hypothesis-fixt |
| #73 | Circadian Glymphatic Rescue Therapy (Melatonin-focused) | MTNR1A | 0.712 | $0.56 | sda-2026-04-01-gap-v |
| #74 | Early Proteasome Restoration Therapy | PSMC | 0.712 | $0.56 | SDA-2026-04-03-gap-a |
| #75 | HDAC3-Selective Inhibition for Clock Reset | HDAC3 | 0.710 | $0.58 | sda-2026-04-01-gap-v |
| #76 | H4: Senomorphic Compounds Preserve Astrocyte Function While Reversing Senescence | MTOR; MEGF10; MERTK | 0.710 | $0.59 | SDA-2026-04-06-gap-d |
| #77 | Metabolic Circuit Breaker via Lipid Droplet Modulation | PLIN2 | 0.709 | $0.60 | sda-2026-04-01-gap-0 |
| #78 | Autophagosome Maturation Checkpoint Control | STX17 | 0.709 | $0.59 | sda-2026-04-01-gap-0 |
| #79 | Orexin-Microglia Modulation Therapy | HCRTR2 | 0.707 | $0.59 | sda-2026-04-01-gap-v |
| #80 | Lysosomal Enzyme Trafficking Correction | IGF2R | 0.706 | $0.60 | sda-2026-04-01-gap-0 |
| #81 | Spatiotemporal coupling between TRPML1-mediated lysosomal calcium release and calcineurin nanodomain activation | TRPML1/MCOLN1 | 0.705 | $0.59 | SDA-2026-04-07-gap-p |
| #82 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.705 | $0.64 | test-hypothesis-fixt |
| #83 | Ferroptosis Inhibition for α-Synuclein Neuroprotection | GPX4 | 0.705 | $0.57 | SDA-2026-04-03-gap-a |
| #84 | Nutrient-Sensing Epigenetic Circuit Reactivation | SIRT1 | 0.700 | $0.63 | SDA-2026-04-04-gap-e |
| #85 | SCFA-Producing Bacterial Depletion → Loss of Neuroprotective Microenvironment | HDAC3, GPR41 (FFAR3), GPR43 (FFAR2), Nrf2, HMOX1 | 0.700 | $0.59 | sda-2026-04-01-gap-2 |
| #86 | TFEB-Independent Autophagy Bypass | ULK1 | 0.697 | $0.56 | SDA-2026-04-03-gap-d |
| #87 | Lysosomal Calcium Channel Modulation Therapy | MCOLN1 | 0.697 | $0.58 | sda-2026-04-01-gap-0 |
| #88 | Temporal Microglial State Switching | Optogenetic constructs, ion channels | 0.695 | $0.58 | SDA-2026-04-04-gap-n |
| #89 | Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy | ALOX15 | 0.695 | $0.56 | sda-2026-04-01-gap-0 |
| #90 | Palmitoylation-Targeted BACE1 Trafficking Disruptors | BACE1 | 0.693 | $0.55 | SDA-2026-04-01-gap-l |
| #91 | Sphingomyelin Synthase Activators for Raft Remodeling | SGMS1/SGMS2 | 0.692 | $0.56 | SDA-2026-04-01-gap-l |
| #92 | cGAS-STING Senescence Circuit Disruption | CGAS, STING1 | 0.691 | $0.58 | SDA-2026-04-03-gap-a |
| #93 | TFEB-Dependent Lysosome Biogenesis | TFEB/TFE3 | 0.690 | $0.58 | SDA-2026-04-07-gap-p |
| #94 | Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurodegeneration in FTD-GRN | GRN, SLC16A3 (MCT4) | 0.690 | $0.59 | SDA-2026-04-02-gap-2 |
| #95 | Ganglioside Rebalancing Therapy | ST3GAL2/ST8SIA1 | 0.690 | $0.54 | SDA-2026-04-01-gap-l |
| #96 | Lysosomal Positioning Dynamics Modulation | LAMP1 | 0.686 | $0.56 | sda-2026-04-01-gap-0 |
| #97 | hnRNPA2B1-Mediated Structural Remodeling Controls lncRNA-0021 Accessibility for miR-6361 Sequestration | hnRNPA2B1, lncRNA-0021 (RBP-bound state) | 0.684 | $0.57 | SDA-2026-04-26-gap-p |
| #98 | Astrocyte-Selective APOE4 Silencing via Lipid Nanoparticles | APOE4 | 0.682 | $0.58 | SDA-2026-04-03-gap-d |
| #99 | HDAC6 Activation as SCFA-Mediated Neuroprotective Mechanism | HDAC6, HSP90AA1 | 0.682 | $0.57 | SDA-2026-04-12-gap-d |
| #100 | Differential Ubiquitin Chain Topology Creates 'Invisible' Surface on Pathological Stress Granules | TRIM21, G3BP1, OTUD1/OTUD7B | 0.682 | $0.58 | SDA-2026-04-06-gap-p |
| #101 | mTORC1 Reactivation as Autophagy-Senescence Divergence Point Marker | MTOR, RPTOR, RPS6KB1, TSC1, TSC2 | 0.682 | $0.55 | SDA-2026-04-07-gap-d |
| #102 | Flotillin-1 Stabilization Compounds | FLOT1 | 0.681 | $0.54 | SDA-2026-04-01-gap-l |
| #103 | Autophagy-Lysosomal Degradation of IBA1 in Stressed Microglia | LC3/P62/SQSTM1 | 0.681 | $0.58 | SDA-2026-04-07-gap-p |
| #104 | NLRP3/Mitophagy Coupling Modulation | NLRP3 | 0.681 | $0.56 | SDA-2026-04-03-gap-i |
| #105 | R-Loop Resolution Enhancement Therapy | SETX | 0.680 | $0.56 | sda-2026-04-01-gap-v |
| #106 | Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution | GPR37 | 0.680 | $0.56 | sda-2026-04-01-gap-0 |
| #107 | Pharmacological EZH2 Inhibition Resets Polycomb-Mediated Repression of Synaptic Transmission Genes in 3xTg-AD Neurons | EZH2/H3K27me3 | 0.680 | $0.58 | SDA-2026-04-04-gap-2 |
| #108 | TFEB-mediated transcriptional upregulation of lysosomal genes as a therapeutic strategy for AD | TFEB (TFEC) | 0.679 | $0.58 | SDA-2026-04-04-gap-l |
| #109 | Dynamic Lactate-Pyruvate Ratio as Therapeutic Stratification Biomarker | SLC16A1 | 0.677 | $0.54 | SDA-2026-04-04-gap-d |
| #110 | Cell-Type Specific TFEB Modulation | TFEB | 0.677 | $0.57 | SDA-2026-04-03-gap-d |
| #111 | Metabolic Reprogramming via Microglial Glycolysis Inhibition | HK2 | 0.672 | $0.56 | sda-2026-04-01-gap-v |
| #112 | Astrocytic-Mediated Tau Clearance Dysfunction via TREM2 Signaling | TREM2 | 0.672 | $0.56 | SDA-2026-04-03-26abc |
| #113 | Partial Neuronal Reprogramming via Modified Yamanaka Cocktail | OCT4 | 0.672 | $0.56 | SDA-2026-04-04-gap-e |
| #114 | OPTN/TBK1 mutations create selective vulnerability by blocking PINK1-Parkin-independent mitophagy in lower motor neurons | OPTN | 0.670 | $0.58 | SDA-2026-04-08-gap-p |
| #115 | Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation | KCNK2 | 0.668 | $0.55 | sda-2026-04-01-gap-v |
| #116 | Mitochondrial-Lysosomal Contact Site Engineering | RAB7A | 0.668 | $0.55 | sda-2026-04-01-gap-0 |
| #117 | Lipid Droplet Dynamics as Phenotype Switches | DGAT1 and SOAT1 | 0.666 | $0.56 | sda-2026-04-01-gap-0 |
| #118 | LRRK2 Volume Sensor Hijacking Drives Metabolic Dysregulation via SIRT1/PGC1α Suppression | LRRK2 | 0.666 | $0.59 | SDA-2026-04-16-gap-p |
| #119 | RNA Granule Nucleation Site Modulation | G3BP1 | 0.662 | $0.57 | sda-2026-04-01-gap-0 |
| #120 | Vascular mural cell degeneration precedes and exacerbates parenchymal pathology | PDGFRB | 0.661 | $0.55 | SDA-2026-04-04-analy |
| #121 | Axonal Transport Defect: C9orf72 hexanucleotide expansion impairs retrograde autophagosome transport in motor neuron axons | C9orf72 | 0.660 | $0.58 | SDA-2026-04-08-gap-p |
| #122 | GDF15-GFRAL Axis as Systemic Autophagy-Senescence Integrator | GDF15, GFRAL, NTRK2 | 0.659 | $0.58 | SDA-2026-04-07-gap-d |
| #123 | Arginine Methylation Enhancement Therapy | PRMT1 | 0.653 | $0.59 | sda-2026-04-01-gap-0 |
| #124 | Microbial Inflammasome Priming Prevention | NLRP3, CASP1, IL1B, PYCARD | 0.653 | $0.66 | SDA-2026-04-01-gap-2 |
| #125 | Nucleolar Stress Response Normalization | NPM1 | 0.653 | $0.56 | sda-2026-04-01-gap-v |
| #126 | The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction | TFEB | 0.652 | $0.54 | SDA-2026-04-02-gap-v |
| #127 | mTORC1 displacement from lysosomal surface enables calcineurin access to TFEB | mTOR/FRAP1 | 0.650 | $0.57 | SDA-2026-04-07-gap-p |
| #128 | Autophagic Flux Enhancement Synergizes With Chaperones to Clear High-Molecular-Weight Tau Seeds | TFEB, LAMP2A, SQSTM1 | 0.649 | $0.58 | SDA-2026-04-06-gap-d |
| #129 | p62 Liquid-Liquid Phase Separation Nucleates Cross-Organelle Cargo for Coordinated Autophagy | SQSTM1/p62 (SQSTM1), ULK1/FIP200 | 0.649 | $0.57 | SDA-2026-04-07-gap-p |
| #130 | ALS-Linked OPTN/TBK1 Mutations Impair Phosphorylation Cascade Required for Pathological SG Recognition | OPTN, TBK1 | 0.648 | $0.57 | SDA-2026-04-06-gap-p |
| #131 | Ephrin-B2/EphB4 Axis Manipulation | EPHB4 | 0.645 | $0.55 | sda-2026-04-01-gap-0 |
| #132 | Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy | - | 0.644 | $0.56 | SDA-2026-04-15-gap-p |
| #133 | Microglial Metabolic Trained Immunity via mTOR-HIF1α Axis | MTOR/HIF1α | 0.644 | $0.58 | SDA-2026-04-07-gap-d |
| #134 | Cell-Type Specific Metabolic Reprogramming | PPARA | 0.643 | $0.54 | SDA-2026-04-03-gap-s |
| #135 | SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis | HK2/PFKFB3 | 0.643 | $0.64 | sda-2026-04-01-gap-0 |
| #136 | TREM2-Mediated Mitochondrial Dysfunction in Neurodegeneration | TREM2 | 0.642 | $0.54 | SDA-2026-04-03-gap-a |
| #137 | CYP46A1 Suppression for Tau-Mediated Neurodegeneration | CYP46A1 | 0.642 | $0.55 | SDA-2026-04-01-gap-l |
| #138 | Glycine-Rich Domain Competitive Inhibition | TARDBP | 0.640 | $0.56 | sda-2026-04-01-gap-0 |
| #139 | H7: mTOR Hyperactivity Blocks Autophagy, Permitting Tau Seeding | MTOR, ULK1, TFG | 0.640 | $0.57 | SDA-2026-04-02-gap-e |
| #140 | Transglutaminase-2 Cross-Linking Inhibition Strategy | TGM2 | 0.639 | $0.56 | SDA-2026-04-01-gap-9 |
| #141 | Mitochondrial NAD+ Salvage Enhancement | STING1 | 0.639 | $0.55 | SDA-2026-04-03-gap-a |
| #142 | Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention for Severe Neurodevelopmental Forms | SOD1, HTT, TARDBP | 0.638 | $0.55 | SDA-2026-04-03-gap-c |
| #143 | Selective Neuronal Vulnerability Network Targeting | Cell-type specific vulnerability markers | 0.638 | $0.56 | SDA-2026-04-03-gap-a |
| #144 | Stage-Selective TREM2 Agonism — Boosting DAM Phagocytosis in Early Amyloid Phase | TREM2 | 0.637 | $0.58 | SDA-2026-04-02-gap-0 |
| #145 | ER-Mitochondria Calcium Microdomains Couple Mitophagy and ER-Phagy Initiation | ITPR1 (IP3R1), VDAC1, MCU | 0.636 | $0.57 | SDA-2026-04-07-gap-p |
| #146 | TREM2-Dependent Microglial Phagocytosis Acts as a Strain Selection Filter | TREM2 | 0.636 | $0.58 | SDA-2026-04-15-gap-d |
| #147 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.634 | $0.60 | SDA-2026-04-04-gap-t |
| #148 | G3BP1 NTF2L Domain-Mediated mRNP Scaffold Creates Core Exclusion Zone for Autophagy Receptors | G3BP1 | 0.633 | $0.57 | SDA-2026-04-08-gap-p |
| #149 | Palmitoylethanolamide-Based Endocannabinoid Therapy | PPARA | 0.633 | $0.54 | SDA-2026-04-16-gap-b |
| #150 | Disease-Associated Microglia Metabolic Reprogramming | TREM2 | 0.631 | $0.57 | SDA-2026-04-03-gap-s |
| #151 | FOXO3-Longevity Pathway Epigenetic Reprogramming | FOXO3 | 0.630 | $0.55 | sda-2026-04-01-gap-v |
| #152 | Autophagosome-Lysosome Fusion Defects as Primary Driver of α-Synuclein Propagation | VPS41, STX17, HOPS complex, TRPML1 (MCOLN1) | 0.630 | $0.57 | SDA-2026-04-02-gap-2 |
| #153 | Restoration of V-ATPase function reverses lysosomal acidification defect in AD neurons | ATP6V1A, ATP6V0C | 0.630 | $0.57 | SDA-2026-04-04-gap-l |
| #154 | Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring | Disease-causing mutations with integrated reporters | 0.629 | $0.52 | SDA-2026-04-03-gap-c |
| #155 | Microglial TREM2 downregulation impairs damage-associated response in late-stage Alzheimer's disease | TREM2 | 0.626 | $0.57 | SDA-2026-04-04-analy |
| #156 | Heat Shock Protein 70 Disaggregase Amplification | HSPA1A | 0.625 | $0.56 | sda-2026-04-01-gap-0 |
| #157 | Galectin-3 deletion attenuates NLRP3 inflammasome activation downstream of lysosomal membrane permeabilization | LGALS3 | 0.625 | $0.56 | SDA-2026-04-04-gap-l |
| #158 | Autophagy-Senescence Axis Therapeutic Window | ATG7,BCL2,BCL2L1 | 0.624 | $0.58 | SDA-2026-04-04-gap-s |
| #159 | TFEB-PGC1α Mitochondrial-Lysosomal Decoupling | TFEB | 0.622 | $0.53 | SDA-2026-04-03-gap-a |
| #160 | Microglial ACE Enhancement for Amyloid Clearance | ACE | 0.622 | $0.55 | SDA-2026-04-03-gap-a |
| #161 | Sphingolipid Metabolism Reprogramming | CERS2 | 0.620 | $0.54 | sda-2026-04-01-gap-0 |
| #162 | Metabolic Rewiring via SPP1-Induced HIF1α Glycolytic Shift | HIF1A (HIF1α), MTOR (mTORC1), EGLN1 (PHD2) | 0.620 | $0.56 | SDA-2026-04-06-gap-p |
| #163 | Selective cathepsin B inhibition prevents cathepsin leakage-mediated NLRP3 inflammasome activation without impairing normal proteolysis | CTSB | 0.620 | $0.56 | SDA-2026-04-04-gap-l |
| #164 | Lysosomal pH Restoration Upstream of TFEB | ATP6V1A | 0.619 | $0.55 | SDA-2026-04-03-gap-d |
| #165 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.618 | $0.67 | SDA-2026-04-04-gap-t |
| #166 | MFN2-PACS2 Axis at MAMs Coordinates Mitophagy-ER-Phagy Sync | MFN2 (MFN2), PACS2 (PACS2) | 0.615 | $0.56 | SDA-2026-04-07-gap-p |
| #167 | Glial-Autophagy-Senescence Coupling Defines CNS Therapeutic Windows | TFEB, MAPK14, MAPKAPK2, IL6, CXCL1 | 0.614 | $0.56 | SDA-2026-04-07-gap-d |
| #168 | Dose-Response Framework: PINK1/Parkin Mitophagy as the Critical Mediator Linking HBOT Parameters to Tau Clearance | PINK1 | 0.614 | $0.56 | SDA-2026-04-26-gap-p |
| #169 | FUS Mutations Alter Stress Granule Material Properties to Confer Autophagy Resistance | FUS | 0.613 | $0.54 | SDA-2026-04-06-gap-p |
| #170 | Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting | HTT, DMPK, repeat-containing transcripts | 0.613 | $0.55 | SDA-2026-04-03-gap-c |
| #171 | SIRT6-NAD+ Axis Enhancement Therapy | SIRT6 | 0.612 | $0.54 | sda-2026-04-01-gap-v |
| #172 | APOE4 preferentially signals through LRP1 over LDLR, altering endosomal cholesterol trafficking and causing lysosomal cholesterol sequestration that drives lysosomal dysfunction and inflammation | LRP1, NPC1, CTSD | 0.610 | $0.56 | SDA-2026-04-04-gap-a |
| #173 | Temporal TFEB Modulation Therapy | TFEB | 0.609 | $0.54 | SDA-2026-04-03-gap-d |
| #174 | The Glial Ketone Metabolic Shunt Hypothesis | HMGCS2 | 0.608 | $0.55 | SDA-2026-04-02-gap-v |
| #175 | Calmodulin isoform switching from CaMK to calcineurin activation upon lysosomal permeabilization | CALM1/CALM2/CALM3 | 0.607 | $0.56 | SDA-2026-04-07-gap-p |
| #176 | TREM2-Mediated Microglial Checkpoint Therapy | TREM2 | 0.606 | $0.54 | SDA-2026-04-03-gap-s |
| #177 | P2RY12-mediated autophagy inhibition in cerebral VSMCs impairs CAA clearance | P2RY12 | 0.605 | $0.55 | SDA-2026-04-07-gap-p |
| #178 | TREM2-Microglial Clearance Enhancement as Common Mechanism for Injury Prevention | TREM2 | 0.604 | $0.58 | SDA-2026-04-14-gap-p |
| #179 | Selective TFEB Cofactor Enhancement | TFE3 | 0.602 | $0.54 | SDA-2026-04-03-gap-d |
| #180 | LRP1-Dependent Tau Uptake Disruption | LRP1 | 0.600 | $0.72 | SDA-2026-04-04-gap-t |
| #181 | mTORC1 Hyperactivation Impairs Autophagic Flux and Drives Senescence | MTOR/TFEB/TFE3 | 0.600 | $0.55 | SDA-2026-04-06-gap-p |
| #182 | H4: Hyperconnected Hub Status Creates Proteostatic Traffic Jams | ERN1 (IRE1α), TFG, ATG9A | 0.600 | $0.55 | SDA-2026-04-02-gap-e |
| #183 | Cytosolic TDP-43 aggregation sequesters SNAP29 and syntaxin-17, blocking autophagosome-lysosome fusion | TARDBP | 0.600 | $0.56 | SDA-2026-04-08-gap-p |
| #184 | OPC differentiation blockade contributes to white matter degeneration in early-stage AD | PDGFRA | 0.599 | $0.55 | SDA-2026-04-04-analy |
| #185 | Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits | PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes | 0.599 | $0.52 | SDA-2026-04-03-gap-c |
| #186 | Netrin-1 Gradient Restoration | NTN1 | 0.595 | $0.54 | sda-2026-04-01-gap-0 |
| #187 | VCP-Mediated Autophagy Enhancement | VCP | 0.595 | $0.64 | SDA-2026-04-04-gap-t |
| #188 | Multiplexed Base Editing for Simultaneous Neuroprotective Gene Activation | SOD1, TARDBP, BDNF, GDNF, IGF-1 | 0.590 | $0.53 | SDA-2026-04-03-gap-c |
| #189 | TREM2-Mediated Microglial Dysfunction Disrupts Oligodendrocyte Tau Clearance Networks | TREM2 | 0.589 | $0.56 | SDA-2026-04-03-26abc |
| #190 | AP1S1-Mediated Vesicular Transport Restoration | AP1S1 | 0.588 | $0.54 | SDA-2026-04-03-gap-a |
| #191 | Mitochondrial-Lysosomal Coupling Enhancer | LAMTOR1 | 0.585 | $0.54 | SDA-2026-04-03-gap-d |
| #192 | P2RY12-driven autophagy impairment in cerebral VSMCs mediates BBB breakdown and neurovascular unit dysfunction | P2RY12 | 0.585 | $0.55 | SDA-2026-04-07-gap-p |
| #193 | ALS-Associated G3BP1/2 Mutations Disrupt TRIM21 Binding Interfaces | G3BP1, G3BP2 | 0.585 | $0.55 | SDA-2026-04-06-gap-p |
| #194 | FcRn Transport Bypass Strategy | LDLR | 0.585 | $0.51 | SDA-2026-04-12-gap-d |
| #195 | PIKFYVE Inhibition Activates Aggregate Exocytosis via PI(3,5)P2→TRPML1→Calcineurin→TFEB Cascade in ALS Motor Neurons | PIKFYVE/MCOLN1/PPP3CB/TFEB | 0.584 | $0.54 | SDA-2026-04-13-gap-p |
| #196 | TREM2-Mediated Selective Aggregate Clearance Pathway | TREM2 | 0.584 | $0.53 | SDA-2026-04-01-gap-9 |
| #197 | Pharmacological P2RY12 inhibition (ticagrelor/clopidogrel) as repurposing probe for neurovascular outcomes | P2RY12 | 0.583 | $0.54 | SDA-2026-04-07-gap-p |
| #198 | Gamma Entrainment Synergy: HBOT-Enhanced Cerebral Perfusion Amplifies SST Interneuron-Targeted Neuromodulation | - | 0.583 | $0.54 | SDA-2026-04-26-gap-p |
| #199 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.582 | $0.58 | SDA-2026-04-04-gap-t |
| #200 | TREM2-Driven Phagocytic Receptor Cascades Determine Mitochondrial Antigen Presentation vs. Intracellular Mitophagy | TREM2 | 0.580 | $0.55 | SDA-2026-04-08-gap-p |
| #201 | Limited Calcium Release Without Sufficient Cathepsin Efflux | TRPML1/MCOLN1, Calcineurin/NFAT | 0.580 | $0.54 | SDA-2026-04-07-gap-p |
| #202 | LAMP-2 replacement therapy prevents lysosomal membrane permeabilization and downstream NLRP3 activation | LAMP2 (LGMN) | 0.580 | $0.54 | SDA-2026-04-04-gap-l |
| #203 | NAD+/SARM1 Axis Provides Metabolic Feedback Coupling Mitophagy to ER-Phagy | SARM1 (SARM1), PARP1, SIRT1, SIRT3 | 0.578 | $0.55 | SDA-2026-04-07-gap-p |
| #204 | TBK1 Phosphorylation State Creates Phospho-Regulated Peripheral Retention Threshold | TBK1 | 0.577 | $0.55 | SDA-2026-04-08-gap-p |
| #205 | Sequential TRPML1 Activation Following Autophagy Priming | MCOLN1 (TRPML1), ATG7 | 0.575 | $0.56 | SDA-2026-04-16-gap-d |
| #206 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.575 | $0.74 | SDA-2026-04-04-gap-t |
| #207 | VPS34 Complex I Subunit Heterogeneity Dictates Organelle-Specific vs. Bulk Autophagy | PIK3C3/VPS34, ATG14L, UVRAG, NRBF2 | 0.571 | $0.54 | SDA-2026-04-07-gap-p |
| #208 | PINK1/PARK2-Mediated Mitophagy Enhancement for Neuroinflammation Control | PINK1 | 0.571 | $0.55 | SDA-2026-04-03-gap-i |
| #209 | Hsp70-based therapy to prevent lysosomal membrane permeabilization and cathepsin release in AD | HSPA1A | 0.570 | $0.54 | SDA-2026-04-04-gap-l |
| #210 | ER Stress Reduction as Adjunctive Therapy to Support Autophagy | HFE (H63D variant) | 0.566 | $0.56 | SDA-2026-04-15-gap-p |
| #211 | Synergistic enhancement of autophagy and lysosomal biogenesis by combined mTOR inhibition and TFEB activation | MTOR, TPCN2, TFEB | 0.565 | $0.54 | SDA-2026-04-04-gap-l |
| #212 | C9orf72-SMCR8-WDR41 Complex Dysfunction in C9-ALS Rescued by PIKFYVE Inhibition via Lysosomal Exocytosis Restoration | C9orf72/SMCR8/RAB7A/PIKFYVE | 0.562 | $0.56 | SDA-2026-04-13-gap-p |
| #213 | Temporal cGAS-STING Activation Stage-Specific Therapeutic Targeting | STING (TMEM173) | 0.560 | $0.54 | SDA-2026-04-07-gap-p |
| #214 | TFEB Activation Clears Tau-Loaded Endolysosomal Compartments, Preventing Release for Transcellular Spreading | TFEB | 0.560 | $0.54 | SDA-2026-04-04-gap-2 |
| #215 | TRPML1-PINK1/Parkin Axis Coordinates Mitophagy with Lysosomal Biogenesis | MCOLN1, PINK1, PARK2, TFEB, LRRK2 | 0.560 | $0.55 | SDA-2026-04-16-gap-d |
| #216 | AMPK Activation to Restore Autophagy and Clear α-Synuclein Aggregates | - | 0.559 | $0.53 | SDA-2026-04-17-gap-p |
| #217 | Circadian-Gated Maresin Biosynthesis Amplification | ALOX12 | 0.557 | $0.56 | sda-2026-04-01-gap-0 |
| #218 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.555 | $0.55 | test-hypothesis-fixt |
| #219 | Profilin-1 Cytoskeletal Checkpoint Enhancement | PFN1 | 0.554 | $0.53 | SDA-2026-04-03-gap-a |
| #220 | Temporal NLRP3 Inhibition During SPP1-Driven Microglial Activation Windows | NLRP3 | 0.551 | $0.56 | SDA-2026-04-15-gap-p |
| #221 | Gamma-Entrained PV Interneuron Networks Enable Precision p-tau217-Guided lncRNA Exosome Therapy in AD | PVALB, CREB1, lncRNA-0021/lncRNA-9969 | 0.550 | $0.56 | SDA-2026-04-26-gap-p |
| #222 | YWHAG-Mediated TFEB Subcellular Targeting | YWHAG | 0.549 | $0.53 | SDA-2026-04-03-gap-d |
| #223 | TRIM21-Mediated Ubiquitination Creates Peripheral Epitope Gradient via K63-Linked Chain Accumulation | TRIM21 | 0.548 | $0.54 | SDA-2026-04-08-gap-p |
| #224 | HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor | DNAJB6 | 0.544 | $0.51 | SDA-2026-04-01-gap-9 |
| #225 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.541 | $0.47 | test-hypothesis-fixt |
| #226 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.541 | $0.47 | test-hypothesis-fixt |
| #227 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.541 | $0.48 | test-hypothesis-fixt |
| #228 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.541 | $0.47 | test-hypothesis-fixt |
| #229 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.541 | $0.47 | test-hypothesis-fixt |
| #230 | P2Y6R activation by UDP from damaged neurons drives microglial phagocytosis and exosomal re-secretion in mid-to-late disease | P2RY6 | 0.540 | $0.53 | SDA-2026-04-07-gap-d |
| #231 | BAG3-Mediated Hsp70 Substrate Redistribution | HSPA1A/Hsp70, BAG3 | 0.540 | $0.53 | SDA-2026-04-07-gap-p |
| #232 | Microglial Exosome-Mediated Tau Propagation | MAPT | 0.539 | $0.54 | SDA-2026-04-03-26abc |
| #233 | Lysosomal Membrane Repair Enhancement | CHMP2B | 0.538 | $0.56 | sda-2026-04-01-gap-0 |
| #234 | EV-Mediated Epigenetic Reprogramming | EVs/miRNAs | 0.532 | $0.53 | sda-2026-04-12-ev-ad |
| #235 | PI3P Generation at Damaged Lysosomes Promotes Membrane Repair | PIK3C3/VPS34, CHMP2A | 0.530 | $0.53 | SDA-2026-04-07-gap-p |
| #236 | PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria | BNIP3/BNIP3L | 0.529 | $0.52 | SDA-2026-04-01-gap-2 |
| #237 | TREM2 Agonism to Redirect Microglia from Synaptic Pruning to OPTN-Deficient Neuron Protection | TREM2 | 0.521 | $0.53 | SDA-2026-04-14-gap-p |
| #238 | Dysregulated microglial glycolysis via HIF1α activation shifts the balance from neuroprotective surveillance to complement-mediated synapse engulfment | HIF1A, LDHA, LDHB, PKM2, TREM2, AMPK/mTOR | 0.520 | $0.53 | SDA-2026-04-02-gap-s |
| #239 | GATA4 Stabilization and NF-κB Co-activation Identifies Senescent Microglia | GATA4, SQSTM1/p62, NFKB subunits | 0.520 | $0.53 | SDA-2026-04-06-gap-d |
| #240 | Loss of Nuclear Lamin B1 Distinguishes Senescent Microglia from Inflammatory Activation | LMNB1 (Lamin B1) | 0.520 | $0.53 | SDA-2026-04-06-gap-d |
| #241 | NRF2 Activation to Counteract Oxidative Stress from RGS6 Deficiency | - | 0.518 | $0.51 | SDA-2026-04-17-gap-p |
| #242 | Vocal Cord Neuroplasticity Stimulation | CHR2/BDNF | 0.515 | $0.54 | sda-2026-04-01-gap-0 |
| #243 | EV-Mediated Epigenetic Reprogramming | EVs/miRNAs | 0.513 | $0.60 | sda-2026-04-12-ev-ad |
| #244 | Microbial Metabolite-Mediated α-Synuclein Disaggregation | SNCA, HSPA1A, DNMT1 | 0.511 | $0.52 | SDA-2026-04-01-gap-2 |
| #245 | Trans-Synaptic Adhesion Molecule Modulation | NLGN1 | 0.503 | $0.55 | SDA-2026-04-04-gap-t |
| #246 | Autophagy-Lysosomal Flux Impairment Preventing Pathological TDP-43 Clearance | TFEB, LAMP1, LAMP2, GABARAPL1, CTSD | 0.500 | $0.52 | SDA-2026-04-07-gap-p |
| #247 | LRP1 Loss-of-Function Derepresses P2RY12 Expression | LRP1 | 0.500 | $0.52 | SDA-2026-04-07-gap-p |
| #248 | Nucleolar p21-rRNA Co-Aggregation as Irreversible Senescence Gate | NCL, FBL, AMBRA1, CDKN1A | 0.500 | $0.52 | SDA-2026-04-07-gap-d |
| #249 | Temporal NLRP3 Inhibition via SPP1-Mediated Mitophagy Enhancement During Critical Neuroinflammatory Windows | NLRP3 | 0.496 | $0.52 | SDA-2026-04-15-gap-p |
| #250 | TREM2-Mediated Microglial Metabolic Reprogramming Accelerates Tau Pathological Spread | TREM2 | 0.494 | $0.53 | SDA-2026-04-03-26abc |
| #251 | Lamin B1 Degradation as Irreversibility Gate | LMNB1, LMNB2, NCOA4, SQSTM1 | 0.493 | $0.50 | SDA-2026-04-07-gap-d |
| #252 | GluN2B-Regulated Microglial Phagocytosis of Tau Aggregates via CX3CR1 Signaling | GRIN2B | 0.491 | $0.52 | SDA-2026-04-03-26abc |
| #253 | G3BP1-TDP-43 Cross-Seeding Drives Co-Aggregation That Prion-Spreads Across Neural Circuits | TARDBP | 0.490 | $0.51 | SDA-2026-04-06-gap-p |
| #254 | Kinesin-Dependent Peripheral Microtubule Transport Maintains Receptor Exclusion from SG Core | KIF5B/KIF5C | 0.486 | $0.51 | SDA-2026-04-08-gap-p |
| #255 | PINK1/PARK2-LC3 Mitophagy Enhancement | PINK1 | 0.485 | $0.50 | SDA-2026-04-03-gap-i |
| #256 | TFEB-Mediated Lysosomal Biogenesis Enhancement for NLRP3 Inflammasome Regulation | TFEB | 0.485 | $0.50 | SDA-2026-04-03-gap-i |
| #257 | Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery | RAB27A/LAMP2B | 0.482 | $0.47 | SDA-2026-04-01-gap-2 |
| #258 | Isoform-Selective Hsp70 Targeting Overcomes Stoichiometric Imbalance in Advanced Pathology | HSPA1A, DNAJB6, DNAJB8 | 0.481 | $0.53 | SDA-2026-04-06-gap-d |
| #259 | Enteric Nervous System Prion-Like Propagation Blockade | TLR4, SNCA | 0.480 | $0.48 | SDA-2026-04-01-gap-2 |
| #260 | FUS-ALS-Specific Ferroptosis Vulnerability Through NCOA4-Mediated Ferritinophagy Targeting | NCOA4 | 0.480 | $0.52 | SDA-2026-04-16-gap-f |
| #261 | Optogenetic Control of Mitochondrial Transfer Networks | ChR2 | 0.476 | $0.47 | SDA-2026-04-01-gap-2 |
| #262 | Lysosomal Accumulation-Induced V-ATPase Inhibition (Osmotic Trapping) | ATP6V0C, ATP6V1 subunits (V-ATPase complex) | 0.470 | $0.50 | SDA-2026-04-08-gap-p |
| #263 | CD44-Mediated Src/PI3K/Akt Signaling Cascade | CD44, SRC, PI3K p85 (PIK3R1), MTOR | 0.470 | $0.50 | SDA-2026-04-06-gap-p |
| #264 | Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption | PHB2 | 0.469 | $0.46 | SDA-2026-04-01-gap-9 |
| #265 | RNA-Binding Competition Therapy for TDP-43 Cross-Seeding | TARDBP | 0.465 | $0.45 | SDA-2026-04-01-gap-9 |
| #266 | Liquid-Liquid Phase Separation (LLPS) Saturation Partitioning Excludes Autophagy Receptors from SG Core | SQSTM1/CALCOCO2 | 0.461 | $0.50 | SDA-2026-04-08-gap-p |
| #267 | DNMT3A-Mediated de novo Methylation Corrects 'Epigenetic Scars' at Polycomb Targets | DNMT3A | 0.460 | $0.53 | SDA-2026-04-10-gap-2 |
| #268 | Alpha-Beta Oscillation Coupling Enhances lncRNA-9969-Mediated Autophagy Through SST Interneuron-Specific ceRNA Networks | SST, CREB1, lncRNA-9969, neuronal autophagy pathway | 0.460 | $0.51 | SDA-2026-04-26-gap-p |
| #269 | C1q Inhibition Prevents Synaptic Mitochondrial Dysfunction via Microglial-Neuronal Cross-Talk Normalization | C1QA/C1QB/C1QC | 0.455 | $0.49 | SDA-2026-04-15-gap-p |
| #270 | PGC1α Activation in PV+ Interneurons Bypasses Mitophagy Deficit to Restore Gamma Oscillations | PPARGC1A | 0.455 | $0.50 | SDA-2026-04-15-gap-p |
| #271 | Mitochondrial Damage-Triggered SPP1 Inflammasome Coupling | SPP1 | 0.453 | $0.50 | SDA-2026-04-15-gap-p |
| #272 | TREM2-SYK Signaling Axis Couples OxPC Recognition to Phagocytic Clearance | TREM2 (Triggering receptor expressed on myeloid cells 2) + SYK (spleen tyrosine kinase) | 0.453 | $0.51 | SDA-2026-04-13-gap-p |
| #273 | Parallel Multi-Pathway Convergence on TFEB Activation | Multiple convergence points; TFEB as master regulator | 0.450 | $0.49 | SDA-2026-04-08-gap-p |
| #274 | Metabolic Reprogramming Toward GAPDH Inhibition | GAPDH, HK2 | 0.450 | $0.52 | SDA-2026-04-07-gap-p |
| #275 | MITF Acts as the Primary Transcriptional Effector Downstream of HDAC1/2 Deletion, Driving the DAM2 Lysosomal Program Through De-repression of Phagocytic Enhancers | MITF | 0.444 | $0.50 | SDA-2026-04-13-gap-p |
| #276 | Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-9969 Exosome Therapy Precision in Early AD | lncRNA-9969 | 0.431 | $0.51 | SDA-2026-04-26-gap-p |
| #277 | Calcineurin-FUNDC1 Axis as a Master Switch for Mitophagy vs. Apoptotic Cell Death | PPP3CA (Calcineurin A) | 0.430 | $0.49 | SDA-2026-04-08-gap-p |
| #278 | GSK3β Inhibition to Prevent α-Synuclein Phosphorylation and Aggregation | - | 0.429 | $0.48 | SDA-2026-04-17-gap-p |
| #279 | Microbiome-Derived Tryptophan Metabolite Neuroprotection | AHR, IL10, TGFB1 | 0.427 | $0.45 | SDA-2026-04-01-gap-2 |
| #280 | Alpha-Theta Oscillation Modulation Enhances lncRNA-9969-Mediated Autophagy Through SST Interneuron-Specific ceRNA Networks | SST, CREB1, lncRNA-9969, neuronal autophagy pathway | 0.421 | $0.49 | SDA-2026-04-26-gap-p |
| #281 | cAMP/PKA-Dependent Transcription Factor Activation via Nutrient Stress Sensing | PRKACA, CREB1, CRTC2 | 0.420 | $0.48 | SDA-2026-04-08-gap-p |
| #282 | Differential Calpain-Mediated Cleavage of Apoptotic vs. Autophagic Substrates | CAPN1/CAPN2 | 0.420 | $0.49 | SDA-2026-04-07-gap-p |
| #283 | Cathepsin-Dependent Processing of Pro-Drug Enzymes | CTSD, Unknown substrate X | 0.400 | $0.48 | SDA-2026-04-07-gap-p |
| #284 | Test: TREM2 enhances amyloid clearance | TREM2 | 0.400 | $0.47 | test-hypothesis-fixt |
| #285 | LRP1-Autophagy BBB Permeabilization for Antibody Transport | LRP1; ATG7; OPTN (autophagy pathway); CLDN5 (tight junctions) | 0.380 | $0.47 | SDA-2026-04-02-gap-b |
| #286 | P2RY12 activation induces cellular senescence in cerebral VSMCs, driving neurodegeneration via SASP secretion | P2RY12 | 0.373 | $0.47 | SDA-2026-04-07-gap-p |
| #287 | Reticulocalbin-2 bridges calcineurin to lysosomal membranes for Ca2+-dependent activation | RCN2 | 0.360 | $0.46 | SDA-2026-04-07-gap-p |
| #288 | Combination Gene Therapy Targeting RGS6 and Parkin or PINK1 to Address Mitochondrial Dysfunction | PINK1 | 0.317 | $0.46 | SDA-2026-04-17-gap-p |
| #289 | [Archived Hypothesis] | - | 0.300 | $0.30 | legacy-pre-pipeline- |
| #290 | P2RY12 rs2046934 polymorphism modifies neurodegeneration risk by altering cerebral vascular autophagy capacity | P2RY12 (rs2046934) | 0.273 | $0.43 | SDA-2026-04-07-gap-p |
| #291 | TYROBP Causal Network Inhibition for Microglial Repolarization | - | 0.105 | $0.42 | SDA-NEUROINFLAM-BIOM |